NASDAQ:TENX - Tenax Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 168.82 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.86
▼ -0.02 (-1.06%)

This chart shows the closing price for TENX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tenax Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TENX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TENX

Analyst Price Target is $5.00
▲ +168.82% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Tenax Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 168.82% upside from the last price of $1.86.

This chart shows the closing price for TENX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Tenax Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020HC WainwrightInitiated CoverageBuy$5.00N/A
5/18/2017LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$50.00High
(Data available from 7/24/2016 forward)
Tenax Therapeutics logo
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $1.86
Low: $1.86
High: $1.88

50 Day Range

MA: $1.98
Low: $1.81
High: $2.22

52 Week Range

Now: $1.86
Low: $0.80
High: $3.68

Volume

19,672 shs

Average Volume

1,226,889 shs

Market Capitalization

$27.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Tenax Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Tenax Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for TENX.

What is the current price target for Tenax Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Tenax Therapeutics in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 168.8%. HC Wainwright has the highest price target set, predicting TENX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Tenax Therapeutics in the next year.
View the latest price targets for TENX.

What is the current consensus analyst rating for Tenax Therapeutics?

Tenax Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TENX will outperform the market and that investors should add to their positions of Tenax Therapeutics.
View the latest ratings for TENX.

What other companies compete with Tenax Therapeutics?

How do I contact Tenax Therapeutics' investor relations team?

Tenax Therapeutics' physical mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company's listed phone number is 919-855-2100 and its investor relations email address is [email protected] The official website for Tenax Therapeutics is www.tenaxthera.com.